Floatz logo

Choline Salicylate

Histiocytic And Dendritic Cell Neoplasm

Mayo ClinicSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Histiocytic And Dendritic Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
Selpercatinib
National Cancer Institute (NCI)
Phase 2CCC
Panitumumab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
s241656
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 11 →

Same molecule, other indications

Choline Salicylate is also rated in:

Hodgkins lymphomaDormant
CC
Indicative · Phase 1
47 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative · Phase 1
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →